BCAL Diagnostics Limited (ASX: BDX) - Share Price
Current share price for BDX : $0.065 0.011 (20.37%)+
BCAL Diagnostics Limited (BDX) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is an Australian health care company engaged in early cancer detection. It launched its first test BREASTEST plus as a 'rule-out' test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTEST is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women.
BDX General Information +
| ASX Code | BDX |
| Website | N/A |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 23 |
| BDX Share Price | $0.065 |
| Day High | $0.065 |
| Day Low | $0.055 |
| Last Close | $0.054 |
| BDX Share Price Movement | $0.01 ( 20.37% ) |
Prices as at 16:40, 5 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
BCAL Diagnostics Limited (BDX) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from BCAL Diagnostics Limited (BDX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
BCAL Diagnostics Limited (BDX) price-sensitive announcements
BDX - Quarterly Activities/Appendix 4C Cash Flow Report
BCAL Diagnostics Limited’s Appendix 4C and September 2026 quarterly activities report outl
BCAL Diagnostics Limited (BDX)
30 Oct 2026 | 11:40 AM
30 Oct 2026 | 11:40 AM
BDX - GSS: Response to Media Speculation & BCAL letter to GSS
Genetic Signatures Limited issued this ASX announcement in response to media speculation a
BCAL Diagnostics Limited (BDX)
16 Oct 2026 | 8:25 PM
16 Oct 2026 | 8:25 PM
BDX - BREASTESTplus 2 clinically validated
BCAL Diagnostics announced that its next-generation BREASTESTplus 2 blood test has complet
BCAL Diagnostics Limited (BDX)
30 Sep 2026 | 8:48 AM
30 Sep 2026 | 8:48 AM
BDX - BCAL Introduces Avantect Multi-Cancer Early Detection Test
BCAL Diagnostics Limited announced the phased Australian launch of Avantect® Multi-Cancer,
BCAL Diagnostics Limited (BDX)
23 Sep 2026 | 10:43 AM
23 Sep 2026 | 10:43 AM
BCAL Diagnostics Limited (BDX) Recent ASX Announcements
BDX Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$7.37 | -$2.00 | 0.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$7.24 | -$2.00 | -22.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$6.40 | -$2.60 | 8.30% | 0.00 | 0.00 | 0.00% | 0.0% |
BDX Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| BCAL Diagnostics Limited (BDX) | $26M | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| CSL Limited (CSL) | $95,363M | 0.7309 | -0.4401 | 0.0602 | 12.3111 | 21.9864 | 20.7382 | 2.14% | 2.14% | 2.21% |
| Mesoblast Limited (MSB) | $2,811M | -0.4501 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 981.8182 | 0.00% | 0.00% | 0.00% |
| PYC Therapeutics Limited (PYC) | $1,773M | -0.3971 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $4,424M | -1.3893 | 0.0000 | -0.5224 | 0.0000 | 153.3019 | 320.9877 | 0.00% | 0.00% | 0.00% |
BDX Directors
| Name | Position | Start Date |
|---|---|---|
| Ms Jayne Andrea Shaw | Non-Executive Chairman, Non-Executive Director | 15 Feb 2010 |
| Mr David George Darling | Non-Executive Director | 1 Mar 2024 |
| Mr Mark Steven McConnell | Non-Executive Director | 1 Feb 2026 |
| Dr John Hurrell | Non-Executive Director | 2 Apr 2024 |
| Mr Jonathan Alfred Grey Trollip | Non-Executive Director | 23 Dec 2020 |
BCAL Diagnostics Limited (BDX) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 20 Mar 2026 | SHAW, Jayne | Buy | Indirect Shares | 225,000 | $0.097 | $21,835.000 |
| 18 Mar 2026 | SHAW, Jayne | Buy | Indirect Shares | 85,000 | $0.100 | $8,477.000 |
| 16 Mar 2026 | SHAW, Jayne | Buy | Indirect Shares | 300,000 | $0.098 | $29,251.000 |
See all changes in directors' interest & trades for BCAL Diagnostics Limited (BDX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
BDX Management
| Name | Position |
|---|---|
| Anne Louise Arnett | Chief Executive Officer |
| Guy Adrian Robertson | Chief Financial Officer,Company Secretary |
BDX Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in BCAL Diagnostics Limited (BDX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 54,985,789 (14.92%) | Capital Property Corporation Pty Ltd |
| 32,670,387 (8.86%) | Jayne Andrea Shaw |
| 28,492,075 (7.73%) | Mera Vale No 2 Pty Ltd |
| 27,937,205 (7.58%) | Ron & Ann Marie Phillips |
BDX Calendar of Events
| Date | Event |
|---|---|
| 27 August 2027 | Report (Annual) |
| 27 August 2027 | Report (Prelim) |
| 17 February 2027 | Report (Interim) |
| 16 February 2027 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
